Providing progressive cancer treatment and compassionate care.

Cancer News – 2016

  • Vectibix® Improves Survival in Colorectal Cancer, Demonstrates Importance of Tissue Testing

    The addition of Vectibix® (panitumumab) to best supportive care improves survival over best standard care alone among colorectal cancer patients who have stopped responding to chemotherapy. However, the benefit is only seen with patients who have no RAS mutations, or those with only the KRAS exon 2 mutation. These results were recently presented at the … Continue reading "Vectibix® Improves Survival in Colorectal Cancer, Demonstrates Importance of Tissue Testing" […]

  • Combo Therapy of Kyprolis plus Dexamethasone Approved for Recurrent Multiple Myeloma

    The United States Food and Drug Administration (FDA) recently approved a new treatment combination consisting of Kyprolis (carfilzomib) plus dexamethasone for patients with relapsed or refractory multiple myeloma. Multiple myeloma is a type of blood cancer that affects certain immune cells called plasma cells. Healthy plasma cells produce proteins called antibodies that are an important … Continue reading "Combo Therapy of Kyprolis plus Dexamethasone Approved for Recurrent Multiple Myeloma" […]

  • ASCO Publishes Breast Cancer Survivorship Guidelines

    The American Society of Clinical Oncology (ASCO), in collaboration with the American Cancer Society (ACS), have released updated guidelines regarding follow-up care for breast cancer survivors. The updated guidelines were recently published in the Journal of Clinical Oncology. There is an estimated 3.1 million breast cancer survivors alive today in the United States. At present, … Continue reading "ASCO Publishes Breast Cancer Survivorship Guidelines" […]

  • Atezolizumab Provides Long-Lasting Anti-Cancer Responses in Advanced Bladder Cancer

    The immunotherapeutic agent, atezolizumab, which is still in investigative stages, provides high rates of anti-cancer responses among patients with advanced bladder cancer. These results were recently presented at the 2016 Genitourinary Cancers Symposium of the American Society of Clinical Oncology (ASCO GU). Urothelial carcinoma (formerly known as transitional cell carcinoma) is a cancer involving parts … Continue reading "Atezolizumab Provides Long-Lasting Anti-Cancer Responses in Advanced Bladder Cancer" […]

  • Quality of Life Helps Determine Type of Hormone Treatment in Early Breast Cancer

    Quality of life issues and different side effects caused by treatment may help determine which type of hormone therapy is most appropriate for postmenopausal women with ductal carcinoma in situ, particularly among women 60 years of age or older. These results were recently published in The Lancet. Hormone-positive breast cancers, which comprise approximately 75% of … Continue reading "Quality of Life Helps Determine Type of Hormone Treatment in Early Breast Cancer" […]

  • Blincyto® is Promising New Treatment Option for Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia

    Amgen, a biotechnology company, has announced that their immunotherapy drug Blincyto® (blinatumomab) appears promising in the treatment of adults with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). The company announced findings from a Phase 2 trial in a recent press release. Acute lymphoblastic leukemia is a fast-growing cancer of the white blood cells. Relapsed/refractory ALL in … Continue reading "Blincyto® is Promising New Treatment Option for Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia" […]

  • Atezolizumab Plus Abraxane Promising New Treatment for Triple-Negative Breast Cancer

    The investigative agent, atezolizumb, in addition to the chemotherapy agent, Abraxane (nab-paclitaxel), provides high anti-cancer responses among patients with triple-negative breast cancer. These results were recently presented at the 2015 annual San Antonio Breast Cancer Symposium. Approximately 10-20% of breast cancers are referred to as triple-negative breast cancer (TNBC). These types of cancers are both … Continue reading "Atezolizumab Plus Abraxane Promising New Treatment for Triple-Negative Breast Cancer" […]

  • Conjugate Drug Extends Survival in Patients with Advanced HER2-Positive Breast Cancer

    Patients with metastatic, HER2-positive breast cancer who received a combination antibody/chemotherapy drug in a phase 3 clinical trial survived longer, on average, than patients receiving other treatments. Researchers from Dana-Farber Cancer Institute reported the findings at the 2015 San Antonio Breast Cancer Symposium. The TH3RESA trial, which enrolled more than 600 participants in the U.S. … Continue reading "Conjugate Drug Extends Survival in Patients with Advanced HER2-Positive Breast Cancer" […]

  • American College of Rheumatology Releases Rheumatoid Arthritis Treatment Guidelines for Patients with Cancer

    The ACR 2015 Rheumatoid Arthritis (RA) treatment guidelines were published after nearly a year of review and revision by the panel. The guideline committee recommends that individuals with RA and cancer be treated in the following manner: Previous Melanoma and Non-Melanoma Skin Cancer: Established RA patients with moderate or high disease activity and a history … Continue reading "American College of Rheumatology Releases Rheumatoid Arthritis Treatment Guidelines for Patients with Cancer" […]

  • FDA Clears Marketing Approval for Device to Reduce Hair Loss during Chemotherapy

    The United States Food and Drug Administration (FDA) cleared for marketing the first cooling cap to reduce hair loss due to chemotherapy. The cooling cap (Dignitana DigniCap Cooling System) is to be used for female breast cancer patients who are undergoing chemotherapy. Certain types of chemotherapy are strongly associated with causing hair loss, whereupon hair … Continue reading "FDA Clears Marketing Approval for Device to Reduce Hair Loss during Chemotherapy" […]